Investor Presentaiton

10 Darovasertib - Darovasertib – Potential to Broadly Impact Uveal Melanoma Potential First-in-Class and Best-in-Class in (Neo)adjuvant UM and Metastatic UM Mutations in GNAQ / GNA11 activate PKC Signaling, a genetic driver of Uveal Melanoma anna GNAQ or GNA11 11. PIP DAG PKC RASGRP3 RAS BY GDP GTP q/11 q/11 Q209L IP MARCKS Daro Ca2 Ca2+ Daro Mono Rationale in Primary UM Single Agent Daro Induces Tumor Regression Uveal Melanoma Xenograft (92.1 mutant GNAQ) 1200 Vehicle Daro 150 mg/kg BID RAF MEK P ERK Darovasertib is an oral, potent and selective PKC inhibitor GNAQ or GNA11 (~95%) and other upstream mutations activate PKC signaling in UM and MUM patients UM is typically treated with radiation and/or enucleation, with no approved systemic therapies for Neoadjuvant UM MUM occurs in approximately 50% of UM patients and predominantly as liver metastasis in ~90% of MUM patients, with no approved therapies for HLA-A*02:01 negative MUM Daro + Crizo Combo Rationale for Use in Metastatic Uveal Melanoma (MUM) Daro Phase 1 Monotherapy Efficacy Association with CMET Expression 6 5 радра88 + 2Pfizer Activation of PKC and CMET Pathways with Observed CMET Overexpression in MUM Liver Metastases PKC Signaling HGF/MET Signaling CMET CMETI wwwwwwww Tumor volume (mm3) mean ± SEM 1000- 800- 600 400 stop dosing 200 re-dose 150mpk bid MET Signature Score 800 0 20 30 40 50 60 70 80 50 100 110 Days post tumor implantation Van Raamsdonk, CD, et. al, Nature 2009; Van Raamsdonk CD, et. al, NEJM 2010; Piperno-Neumann S, et. al, J Clin Oncol 2014 -1 PD SD<6mos SD>=6mos PR Ph 1 Clinical Outcomes PD=Progressive Disease, SD=Stable Disease, PR=Partial Response IDEAYA Data, AACR 2021 + Pfizer Clinical Trial Collaboration and Supply Agreements for Darovasertib + Crizotinib Combination in MUM IDEAYA owns or controls all commercial rights in darovasertib, including in Primary UM and MUM GDP GNAQ or GNA11 Q209L Daro wwwwww PKCб/E Cancer Cell Survival and Proliferation GA IDEA A BIOSCIENCES

View entire presentation